Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17


miR-186 suppressed CYLD expression and promoted cell proliferation in human melanoma.

Qiu H, Yuan S, Lu X.

Oncol Lett. 2016 Oct;12(4):2301-2306. Epub 2016 Aug 11.


Epidermal CYLD inactivation sensitizes mice to the development of sebaceous and basaloid skin tumors.

Jin YJ, Wang S, Cho J, Selim MA, Wright T, Mosialos G, Zhang JY.

JCI Insight. 2016 Jul 21;1(11). pii: e86548.


Necroptosis: an alternative cell death program defending against cancer.

Chen D, Yu J, Zhang L.

Biochim Biophys Acta. 2016 Apr;1865(2):228-36. doi: 10.1016/j.bbcan.2016.03.003. Epub 2016 Mar 8. Review.


LUBAC-Recruited CYLD and A20 Regulate Gene Activation and Cell Death by Exerting Opposing Effects on Linear Ubiquitin in Signaling Complexes.

Draber P, Kupka S, Reichert M, Draberova H, Lafont E, de Miguel D, Spilgies L, Surinova S, Taraborrelli L, Hartwig T, Rieser E, Martino L, Rittinger K, Walczak H.

Cell Rep. 2015 Dec 15;13(10):2258-72. doi: 10.1016/j.celrep.2015.11.009. Epub 2015 Dec 6.


Brooke-Spiegler Syndrome - an underrecognized cause of multiple familial scalp tumors: report of a new germline mutation.

Pinho AC, Gouveia MJ, Gameiro AR, Cardoso JC, Gonçalo MM.

J Dermatol Case Rep. 2015 Sep 30;9(3):67-70. doi: 10.3315/jdcr.2015.1208. eCollection 2015 Sep 30.


Trichoepithelioma: a rare but crucial dermatologic issue.

Mohammadi AA, Seyed Jafari SM.

World J Plast Surg. 2014 Jul;3(2):142-5.


Mutations of epigenetic regulatory genes are common in thymic carcinomas.

Wang Y, Thomas A, Lau C, Rajan A, Zhu Y, Killian JK, Petrini I, Pham T, Morrow B, Zhong X, Meltzer PS, Giaccone G.

Sci Rep. 2014 Dec 8;4:7336. doi: 10.1038/srep07336.


CYLD-mediated signaling and diseases.

Mathis BJ, Lai Y, Qu C, Janicki JS, Cui T.

Curr Drug Targets. 2015;16(4):284-94. Review.


Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in an NF-κB-dependent manner.

Manganaro L, Pache L, Herrmann T, Marlett J, Hwang Y, Murry J, Miorin L, Ting AT, König R, García-Sastre A, Bushman FD, Chanda SK, Young JA, Fernandez-Sesma A, Simon V.

J Virol. 2014 Jul;88(13):7528-40. doi: 10.1128/JVI.00239-14. Epub 2014 Apr 23.


Reversible inactivation of deubiquitinases by reactive oxygen species in vitro and in cells.

Lee JG, Baek K, Soetandyo N, Ye Y.

Nat Commun. 2013;4:1568. doi: 10.1038/ncomms2532.


The role of the c-Jun N-terminal Kinase signaling pathway in skin cancer.

Zhang JY, Selim MA.

Am J Cancer Res. 2012;2(6):691-8. Epub 2012 Nov 20.


A pro-inflammatory role of deubiquitinating enzyme cylindromatosis (CYLD) in vascular smooth muscle cells.

Liu S, Lv J, Han L, Ichikawa T, Wang W, Li S, Wang XL, Tang D, Cui T.

Biochem Biophys Res Commun. 2012 Mar 30;420(1):78-83. doi: 10.1016/j.bbrc.2012.02.118. Epub 2012 Mar 1.


Genetic evidence supporting the association of protease and protease inhibitor genes with inflammatory bowel disease: a systematic review.

Cleynen I, Jüni P, Bekkering GE, Nüesch E, Mendes CT, Schmied S, Wyder S, Kellen E, Villiger PM, Rutgeerts P, Vermeire S, Lottaz D.

PLoS One. 2011;6(9):e24106. doi: 10.1371/journal.pone.0024106. Epub 2011 Sep 8. Review.


Mutant p62P392L stimulation of osteoclast differentiation in Paget's disease of bone.

Sundaram K, Shanmugarajan S, Rao DS, Reddy SV.

Endocrinology. 2011 Nov;152(11):4180-9. doi: 10.1210/en.2011-1225. Epub 2011 Aug 30.


A rare case of multiple segmental eccrine spiradenomas.

Englander L, Emer JJ, McClain D, Amin B, Turner RB.

J Clin Aesthet Dermatol. 2011 Apr;4(4):38-44.


CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels.

Miliani de Marval P, Lutfeali S, Jin JY, Leshin B, Selim MA, Zhang JY.

Cancer Prev Res (Phila). 2011 Jun;4(6):851-9. doi: 10.1158/1940-6207.CAPR-10-0360. Epub 2011 Apr 8.


Identification of a large rearrangement in CYLD as a cause of familial cylindromatosis.

van den Ouweland AM, Elfferich P, Lamping R, van de Graaf R, van Veghel-Plandsoen MM, Franken SM, Houweling AC.

Fam Cancer. 2011 Mar;10(1):127-32. doi: 10.1007/s10689-010-9393-y.

Supplemental Content

Support Center